Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.

Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F, MITO16b/MANGO–OV2/ENGOT–ov17 Investigators

Open source

DOI: 10.1016/s1470-2045(20)30637-9
Published: 2021 Feb
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-20-30637-9,
  title = {Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.},
  author = {Pignata S and Lorusso D and Joly F and Gallo C and Colombo N and Sessa C and Bamias A and Salutari V and Selle F and Frezzini S and De Giorgi U and Pautier P and Bologna A and Orditura M and Dubot C and Gadducci A and Mammoliti S and Ray-Coquard I and Zafarana E and Breda E and Favier L and Ardizzoia A and Cinieri S and Largillier R and Sambataro D and Guardiola E and Lauria R and Pisano C and Raspagliesi F and Scambia G and Daniele G and Perrone F and MITO16b/MANGO–OV2/ENGOT–ov17 Investigators},
  year = {2021},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(20)30637-9},
  url = {https://doi.org/10.1016/s1470-2045(20)30637-9}
}

RIS

TY  - JOUR
TI  - Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
AU  - Pignata S
AU  - Lorusso D
AU  - Joly F
AU  - Gallo C
AU  - Colombo N
AU  - Sessa C
AU  - Bamias A
AU  - Salutari V
AU  - Selle F
AU  - Frezzini S
AU  - De Giorgi U
AU  - Pautier P
AU  - Bologna A
AU  - Orditura M
AU  - Dubot C
AU  - Gadducci A
AU  - Mammoliti S
AU  - Ray-Coquard I
AU  - Zafarana E
AU  - Breda E
AU  - Favier L
AU  - Ardizzoia A
AU  - Cinieri S
AU  - Largillier R
AU  - Sambataro D
AU  - Guardiola E
AU  - Lauria R
AU  - Pisano C
AU  - Raspagliesi F
AU  - Scambia G
AU  - Daniele G
AU  - Perrone F
AU  - MITO16b/MANGO–OV2/ENGOT–ov17 Investigators
PY  - 2021
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(20)30637-9
UR  - https://doi.org/10.1016/s1470-2045(20)30637-9
ER  -

APA

S, P., D, L., F, J., C, G., N, C., C, S., A, B., V, S., F, S., S, F., U, D. G., P, P., A, B., M, O., C, D., A, G., S, M., I, R., E, Z., E, B., L, F., A, A., S, C., R, L., D, S., E, G., R, L., C, P., F, R., G, S., G, D., F, P., & Investigators, M. (2021). Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(20)30637-9

Source records

pubmed · retrieved 2026-09-27T12:04:43.486Z